Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:10 AM
Ignite Modification Date: 2025-12-25 @ 12:10 AM
NCT ID: NCT06639958
Eligibility Criteria: Inclusion Criteria: * Age: \>= 10 years and =\< 25 years * Previously enrolled onto AALL1732 * Consented to the AALL1732 mercaptopurine adherence correlative study * Maintenance therapy has not yet begun * English or Spanish-speaking (patient and parent/other adult) * Planning to receive 6MP (as tablets) during maintenance phase of therapy * Able and willing to use the MEMSĀ® TrackCapā„¢ (e.g., not using a pillbox or prescribed liquid 6MP) * Has a designated parent/other adult who is willing to enter into a mutual agreement with the patient to participate in a daily supervised medication administration routine * Patient/parent/other adult must be willing to use a smartphone to receive medication reminders * Receiving treatment at a Children's Oncology Group (COG) institution in the United States Exclusion Criteria: * Patients who have previously participated in or are currently participating in another intervention clinical trial designed to improve adherence * Regulatory requirements * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Healthy Volunteers: False
Sex: ALL
Minimum Age: 10 Years
Maximum Age: 25 Years
Study: NCT06639958
Study Brief:
Protocol Section: NCT06639958